Biontech Se share price today
(NASDAQ: BNTX)

Name: Biontech Se Share Price Today (NASDAQ: BNTX) - Biontech Se Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Biontech Se share price is $122.08 & ₹10,558.70 as on 24 Jan 2025, 2.30 'hrs' IST

$122.08

▲

6.91

(6%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Biontech Se share price in Dollar and Rupees. Guide to invest in Biontech Se stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Biontech Se, along with analyst recommendations, forecasts, and comprehensive financials.

Biontech Se share price movements

Today's Low: $114.06
Today's High: $122.24
$122.08
6.57%
Downside
Day's Volatility :6.69%
Upside
0.13%
52 Weeks Low: $76.53
52 Weeks High: $131.49
$122.08
37.31%
Downside
52 Weeks Volatility :41.8%
Upside
7.16%

Biontech Se Returns

Period	Biontech Se	Sector (Health Care)	Index (Russel 2000)
3 Months	4.25%	-5.5%	0.0%
6 Months	34.01%	-4.3%	0.0%
1 Year	18.85%	1.6%	0.0%
3 Years	-26.4%	9.8%	-11.0%

Biontech Se Key Statistics

in dollars & INR

Previous Close	$115.17
Open	$114.9
Today's High	$122.24
Today's Low	$114.06
Market Capitalization	$28.1B
Today's Volume	$545.6K
52 Week High	$131.49
52 Week Low	$76.5301
Revenue TTM	$3.0B
EBITDA	$-274.5M
Earnings Per Share (EPS)	$-2.0
Profit Margin	-15.36%
Quarterly Earnings Growth YOY	0.23%
Return On Equity TTM	-2.4%

How to invest in Biontech Se Stock (BNTX) from India?

It is very easy for Indian residents to invest directly in Biontech Se from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biontech Se stock in both Indian Rupees (INR) and US Dollars (USD). Search for Biontech Se or BNTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biontech Se or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biontech Se shares which would translate to 0.007 fractional shares of Biontech Se as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Biontech Se, in just a few clicks!

Returns in Biontech Se for Indian investors in Rupees

Investment Value

₹1,00,000

Biontech Se investment value today

Current value as on today

₹1,27,492

Returns

₹27,492

(+27.49%)

Returns from Biontech Se Stock

₹23,438 (+23.44%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Biontech Se

-12%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Biontech Se on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -12% less investors are searching Biontech Se in the last 30 days versus the previous period.

Global Institutional Holdings in Biontech Se

Baillie Gifford & Co Limited.
3.47%
FMR Inc
2.63%
PRIMECAP Management Company
1.88%
Flossbach von Storch AG
1.82%
BlackRock Inc
0.86%
Temasek Holdings Ltd.
0.75%

Analyst Recommendation on Biontech Se

Buy

54%Buy

37%Hold

8%Sell

Based on 24 Wall street analysts offering stock ratings for Biontech Se(by analysts ranked 0 to 5 stars)

Based on 24 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Biontech Se

What analysts predicted

Upside of 14.13%

Target:

$139.33

Current:

$122.08

Insights on Biontech Se

Price Movement
In the last 6 months, BNTX stock has moved up by 34.7%
Increasing Revenue
BioNTech SE has shown positive revenue growth over the last two quarters. Revenue increased from $128.7 million to $1.24 billion, with an average quarterly growth rate of 89.7%. This indicates strong performance and significant expansion in their financial results.
Increasing Net Profit
Biontech SE has shown a significant improvement in its net profit over the last two quarters. The company's net profit rose from a loss of $807.8 million to a profit of $198.1 million, reflecting an average increase of 507.8% per quarter.
BNTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 40.5% return, outperforming this stock by 25.7%
BNTX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 117.3%
Price to Sales
BioNTech SE (BNTX) has a Price-to-Sales Ratio of 9.1, which means that investors are willing to pay $9.1 for every $1 of sales the company generates. In comparison, investors are willing to pay $16.1 for every $1 of sales for Alnylam Pharmaceuticals, Inc. This indicates that BioNTech SE is valued lower in terms of its sales performance compared to Alnylam Pharmaceuticals.

Biontech Se Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$145.1M	↑ 107.11%
Net Income	$-54.6M	↓ 43.94%
Net Profit Margin	-37.64%	↑ 101.41%

	FY19	Y/Y Change
Revenue	$120.7M	↓ 14.88%
Net Income	$-199.1M	↑ 273.13%
Net Profit Margin	-165.0%	↓ 127.36%

	FY20	Y/Y Change
Revenue	$586.7M	↑ 344.17%
Net Income	$18.5M	↓ 108.48%
Net Profit Margin	3.15%	↑ 168.15%

	FY21	Y/Y Change
Revenue	$21.5B	↑ 3834.42%
Net Income	$11.6B	↑ 67613.82%
Net Profit Margin	54.24%	↑ 51.09%

	FY22	Y/Y Change
Revenue	$18.3B	↓ 8.78%
Net Income	$10.0B	↓ 8.34%
Net Profit Margin	54.5%	↑ 0.26%

	FY23	Y/Y Change
Revenue	$4.2B	↓ 77.94%
Net Income	$1.0B	↓ 90.14%
Net Profit Margin	24.36%	↓ 30.14%

	Q2 FY23	Q/Q Change
Revenue	$971.1M	↓ 29.89%
Net Income	$174.2M	↓ 68.02%
Net Profit Margin	17.94%	↓ 21.39%

	Q3 FY23	Q/Q Change
Revenue	$1.6B	↑ 65.2%
Net Income	$488.8M	↑ 185.12%
Net Profit Margin	30.96%	↑ 13.02%

	Q4 FY23	Q/Q Change
Revenue	$1.6B	↑ 0.0%
Net Income	$499.5M	↑ 0.0%
Net Profit Margin	30.96%	↑ 0.0%

	Q1 FY24	Q/Q Change
Revenue	$203.9M	↓ 87.32%
Net Income	$-342.5M	↓ 168.81%
Net Profit Margin	-167.96%	↓ 198.92%

	Q2 FY24	Q/Q Change
Revenue	$138.5M	↓ 31.4%
Net Income	$-869.2M	↑ 156.36%
Net Profit Margin	-627.66%	↓ 459.7%

	Q3 FY24	Q/Q Change
Revenue	$1.2B	↑ 867.21%
Net Income	$198.1M	↓ 124.52%
Net Profit Margin	15.91%	↑ 643.57%

	FY18	Y/Y Change
Profit	$-33.2M	↓ 12.23%

	FY19	Y/Y Change
Profit	$-150.3M	↑ 363.86%

	FY20	Y/Y Change
Profit	$-270.1M	↑ 64.18%

	FY21	Y/Y Change
Profit	$17.1B	↓ 6907.87%

	FY22	Y/Y Change
Profit	$13.5B	↓ 15.46%

	FY23	Y/Y Change
Profit	$3.5B	↓ 74.81%

	Q2 FY23	Q/Q Change
Profit	$255.6M	↓ 72.18%

	Q3 FY23	Q/Q Change
Profit	$1.4B	↑ 451.74%

	Q4 FY23	Q/Q Change
Profit	$1.4B	↑ 0.0%

	Q1 FY24	Q/Q Change
Profit	$139.7M	↓ 90.11%

	Q2 FY24	Q/Q Change
Profit	$74.1M	↓ 46.38%

	Q3 FY24	Q/Q Change
Profit	$1.1B	↑ 1447.02%

	FY18	Y/Y Change
Operating Cash Flow	$-66.2M	↑ 10.69%
Investing Cash Flow	$-75.6M	↑ 26.46%
Financing Cash Flow	$415.4M	↓ 22326.23%

	FY19	Y/Y Change
Operating Cash Flow	$-220.6M	↑ 241.25%
Investing Cash Flow	$-85.7M	↑ 16.05%
Financing Cash Flow	$425.9M	↑ 4.96%

	FY20	Y/Y Change
Operating Cash Flow	$-16.4M	↓ 93.21%
Investing Cash Flow	$-176.2M	↑ 87.83%
Financing Cash Flow	$1.1B	↑ 133.43%

	FY21	Y/Y Change
Operating Cash Flow	$1.0B	↓ 6703.09%
Investing Cash Flow	$-640.0M	↑ 290.82%
Financing Cash Flow	$106.5M	↓ 89.47%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$879.9M	↓ 219.75%
Investing Cash Flow	$-1.3B	↑ 0.0%
Financing Cash Flow	$-337.3M	↑ 6.76%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$908.4M	↑ 4.89%
Investing Cash Flow	$-1.3B	↑ 0.0%
Financing Cash Flow	$-13.8M	↓ 95.85%

Biontech Se Technicals Summary

Sell

Neutral

Buy

Biontech Se is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Biontech Se Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biontech Se	0.91%	34.01%	18.85%	-26.4%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.95%	-28.33%	12.74%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

Biontech Se Dividend announcements

Biontech Se Dividends June, 2022
In the quarter ending June,2022. Biontech Se has declared dividend of $2.11
Read More

About Biontech Se

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

Organization	Biontech Se
Employees	6133
CEO	Dr. Ugur Sahin M.D.
Industry	Health Technology

Management People of Biontech Se

Name	Title
Dr. Ugur Sahin M.D.	Co-Founder, CEO & Chair of the Management Board
Dr. Ozlem Tureci M.D.	Co-Founder, Chief Medical Officer & Member of Management Board
Mr. Jens H. Holstein	CFO & Member of Management Board
Dr. Sierk Poetting Ph.D.	MD, COO & Member of Management Board
Mr. Ryan Richardson	Chief Strategy Officer, MD & Member of Management Board
Dr. James Timothy Patrick Ryan Ph.D.	Chief Legal & Business Officer & Member of the Management Board
Ms. Lisa Birringer	Senior Vice President of Global Financial Reporting & Accounting
Mr. Zach Taylor	Senior Vice President of Corporate Development & Strategy
Dr. Katalin Kariko Ph.D.	Senior VP & External Consultant for RNA Protein Replacement Therapies
Dr. Oliver Henning Ph.D.	Senior Vice President of Operations

Important FAQs about investing in Biontech Se (BNTX) from India :

What is Biontech Se share price today?

Biontech Se share price today stands at $122.08, Open: $114.90 ; Previous Close: $115.17 ; High: $122.24 ; Low: $114.06 ; 52 Week High: $131.49 ; 52 Week Low: $76.53. The stock opens at $114.90, after a previous close of $115.17. The stock reached a daily high of $122.24 and a low of $114.06, with a 52-week high of $131.49 and a 52-week low of $76.53.

Can Indians buy Biontech Se shares?

Yes, Indians can invest in the Biontech Se (BNTX) from India.

With INDmoney, you can buy Biontech Se at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Biontech Se at zero transaction cost.

How can I buy Biontech Se shares from India?

It is very easy to buy Biontech Se from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biontech Se be purchased?

Yes, you can buy fractional shares of Biontech Se with INDmoney app.

What are the documents required to start investing in Biontech Se stocks?

To start investing in Biontech Se, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.